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Summary and Implications 
Pandemic H1N1 (pH1N1) influenza was first reported 
in the United States in April 2009.  Since then, the virus has 
spread worldwide in both human and swine populations.  
Currently, pH1N1 influenza is the most common H1N1 
virus infecting pigs in the United States.  Vaccination of 
swine against pH1N1 represents the single best method of 
protecting against infection. 
 
Introduction 
 The recent outbreak of pH1N1 highlights the zoonotic 
potential of influenza viruses.  In addition to the pH1N1 
virus, several studies have reported zoonotic transmission of 
swine influenza viruses to humans.  Swine may play an 
important role in the creation of novel reassortant influenza 
viruses that may have human health implications.  
Vaccination of swine against influenza can significantly 
decrease morbidity and therefore decrease the zoonotic 
potential of swine influenza viruses.  In this study we 
demonstrate a rapid response to the pH1N1 outbreak by 
producing a vaccine based on the alphavirus replicon 
technology in less than two months after the initial report.  
We also demonstrate vaccine efficacy of recombinant 
hemagglutinin (HA) and replicon particle vaccines 
following homologous pH1N1 influenza challenge. 
 
Materials and Methods 
 The HA gene from pH1N1 was commercially 
synthesized and inserted into the alphavirus replicon vector 
using previously described methods.  Both recombinant HA 
protein and replicon particles expressing the HA protein 
were produced and used in a vaccination-challenge animal 
study.  Twenty-five total pigs were divided equally among 
five treatment groups.  The group treatments were: 1) sham; 
2) HA RP; 3) recombinant HA high-dose; 4) recombinant 
HA mid-dose; and 5) recombinant HA low-dose.  Pigs 
received respective vaccination treatment on study days 0 
and 21.  All animals were challenged intratracheally with 
pH1N1 virus on study day 47 and were necropsied 5 days 
post-challenge. Sera were collected throughout the study for 
hemagglutination inhibition (HI) serum antibody testing.  
Nasal swabs were collected daily post-challenge for 
quantification of live virus shedding.  At necropsy, pig 
lungs were grossly examined for lesions typical of swine 
influenza, and samples were also collected for 
histopathological analysis.  Animal weights were taken prior 
to challenge and again at necropsy for determination of 
average daily gain (ADG) post-challenge.  All animal work 
was approved by the ISU IACUC. 
 
Results and Discussion 
 All pigs receiving either the HA RP or any dose of 
recombinant HA vaccine developed positive HI antibody 
titers post-vaccination.  Following challenge, all vaccinated 
groups had significantly lower gross lung scores than the 
sham group.  These results correlated with microscopic 
analysis of lung samples which also indicated that 
vaccinated animals had significantly lower histopathological 
scores than the sham animals.  No live virus was detected 
from nasal swab samples collected from HA RP and 
recombinant HA high-dose vaccinated animals at any time 
point post-challenge while all animals in the sham group 
were positive by day 3 post-challenge.  The mid- and low-
dose recombinant HA groups shed significantly less virus 
than the sham group at days 4 and 5 post-challenge. All 
vaccinated groups demonstrated higher ADG than the sham 
group. 
 These results demonstrate that alphavirus replicon-
based HA vaccine are efficacious against pH1N1.  Of 
importance, all vaccinated groups had higher ADG values, 
and decreased nasal shedding of the virus and decreased 
pulmonary disease when compared to the sham group.  In 
addition, we demonstrated that this technology could be 
utilized rapidly to produce vaccines against an emerging 
virus. 
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